Cite
Hanna CR, O'Cathail SM, Graham JS, et al. Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). Radiat Oncol. 2021;16(1):163doi: 10.1186/s13014-021-01888-1.
Hanna, C. R., O'Cathail, S. M., Graham, J. S., Saunders, M., Samuel, L., Harrison, M., Devlin, L., Edwards, J., Gaya, D. R., Kelly, C. A., Lewsley, L. A., Maka, N., Morrison, P., Dinnett, L., Dillon, S., Gourlay, J., Platt, J. J., Thomson, F., Adams, R. A., & Roxburgh, C. S. D. (2021). Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). Radiation oncology (London, England), 16(1), 163. https://doi.org/10.1186/s13014-021-01888-1
Hanna, Catherine R, et al. "Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)." Radiation oncology (London, England) vol. 16,1 (2021): 163. doi: https://doi.org/10.1186/s13014-021-01888-1
Hanna CR, O'Cathail SM, Graham JS, Saunders M, Samuel L, Harrison M, Devlin L, Edwards J, Gaya DR, Kelly CA, Lewsley LA, Maka N, Morrison P, Dinnett L, Dillon S, Gourlay J, Platt JJ, Thomson F, Adams RA, Roxburgh CSD. Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). Radiat Oncol. 2021 Aug 26;16(1):163. doi: 10.1186/s13014-021-01888-1. PMID: 34446053; PMCID: PMC8393812.
Copy
Download .nbib